GoAI
Get started
Allarity Therapeutics, Inc. logo

Allarity Therapeutics, Inc.

ALLR

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.42

−$0.01 · -0.70%

Aug 21, 4:00 PM ET

ALLR company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

43

Fair Value

Momentum

27

Weakening

Sentiment

54

Mixed

Risk resilience

33

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Thomas H. Jensen
Listed since
Dec 21, 2021
Employees
8

Market position

Day range

Current $1.42

52-week range

Current $1.42

Open
$1.43
Previous close
$1.43
Volume
112.29K
0.7× average
Average volume
159.41K
Average daily volume
Market cap
22.59M USD
Beta
0.51
Market reference 1
50-day average
$1.2971
+9.47% above average
200-day average
$1.2293
+15.51% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.24M USD
P/E (TTM)
-1.82×
P/B (TTM)
6.39×
P/S (TTM)
65.49×
EV / EBITDA
-0.2×
Earnings yield
-72.32%
Free cash flow yield
-95.48%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
107.54%
Operating margin
-3128.99%
Net margin
-3575.07%
Return on equity
-114.28%
Return on assets
-61.51%
Return on invested capital
-112.26%

Financial health

Debt / equity
6.3×
Current ratio
2.13×

Financial statements

Income trends

Operating income

−12.61M USD+53.73%

Net income

−11.23M USD+54.19%
Income trends across reported periods−8.91M USD−18.2M USD−27.49M USD−36.79M USDOperating income, FY2021: −26.56M USDOperating income, FY2022: −34.46M USDOperating income, FY2023: −17.13M USDOperating income, FY2024: −27.24M USDOperating income, FY2025: −12.61M USDNet income, FY2021: −26.65M USDNet income, FY2022: −16.06M USDNet income, FY2023: −11.9M USDNet income, FY2024: −24.52M USDNet income, FY2025: −11.23M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −26.56M USD. Operating income FY2022 −34.46M USD. Operating income FY2023 −17.13M USD. Operating income FY2024 −27.24M USD. Operating income FY2025 −12.61M USD. Net income FY2021 −26.65M USD. Net income FY2022 −16.06M USD. Net income FY2023 −11.9M USD. Net income FY2024 −24.52M USD. Net income FY2025 −11.23M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue320K USD————
Cost of goods sold———120K USD106K USD
Gross profit320K USD——−120K USD−106K USD
Research and development6.6M USD6.1M USD7.1M USD6.93M USD14.2M USD
Selling, general, and administrative6.32M USD11.44M USD10.03M USD9.96M USD12.36M USD
Operating expenses12.93M USD27.24M USD17.13M USD34.46M USD26.56M USD
Interest income801K USD533K USD22K USD30K USD—
Interest expense185K USD653K USD498K USD223K USD640K USD
Depreciation and amortization−13K USD9K USD37K USD60K USD106K USD
Operating income−12.61M USD−27.24M USD−17.13M USD−34.46M USD−26.56M USD
Net income−11.23M USD−24.52M USD−11.9M USD−16.06M USD−26.65M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
70%
7 beats, 3 misses, 0 met estimates
Average EPS surprise
-3863.66%
10 comparable reports
Latest EPS result
-0.21
Estimate -0.25 · Beat by 16.00%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.13-3-5.87-8.74Q2 '25BeatQ2 '25No estimateQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q2 2025, reported Apr 4, 2025: actual -4.73, estimate -8.1, surprise +41.61%, Beat. Q2 2025, reported May 9, 2025: actual -0.25, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 15, 2025: actual -0.15, estimate -0.21, surprise +28.57%, Beat. Q4 2025, reported Nov 14, 2025: actual -0.19, estimate -0.23, surprise +17.39%, Beat. Q1 2026, reported Mar 31, 2026: actual -0.19, estimate -0.22, surprise +13.64%, Beat. Q2 2026, reported May 15, 2026: actual -0.17, estimate -0.22, surprise +22.73%, Beat. Q3 2026, reported Aug 14, 2026: actual -0.21, estimate -0.25, surprise +16.00%, Beat. Q4 2026, reported Nov 13, 2026: actual —, estimate -0.25, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates345.12K231.78K118.44K5.1KQ2 '25No estimateQ1 '26MetQ2 '26Met
Q2 2025, reported Apr 4, 2025: actual 6K USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 31, 2026: actual 320K USD, estimate 320K USD, surprise 0.00%, Met estimate. Q2 2026, reported May 15, 2026: actual 25K USD, estimate 25K USD, surprise 0.00%, Met estimate.

Corporate actions

Corporate action history

Stock split

Effective Sep 11, 2024

1:30

Stock split

Effective Apr 9, 2024

1:20

Stock split

Effective Jun 29, 2023

1:40

Stock split

Effective Mar 27, 2023

1:35

ALLR peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ALLR

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
207.87K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research ALLR

research.disclaimer